Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310566 | 0.92 | TLR4 (0.79) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310569 | 0.91 | TLR4 (0.67) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310565 | 0.90 | TLR4 (0.88) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310568 | 0.90 | TLR4 (0.88) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310577 | 0.85 | TLR4 (0.82) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310561 | 0.85 | TLR4 (0.88) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310581 | 0.84 | TLR4 (0.88) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1462506 | 0.84 | TLR4 (1.00) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310595 | 0.84 | TLR4 (1.00) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10310571 | 0.83 | TLR4 (0.70) | TLR4CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087682-A1 | Method for Treating Scleroderma | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087682-A1 | Method for Treating Scleroderma | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-03-26 | — | — | US | disclosed |
| US-8642614-B2 | Toll-like receptor modulators and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642614-B2 | Toll-like receptor modulators and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120178774-A1 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178774-A1 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011038152-A2 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178774-A1 | TOLL-LIKE RECEPTOR MODULATORS AND USES THEREOF | TLR4, TLR3, TLR1 | TLR4 1/4885CYP1A2 3845/4885CYP2D6 4016/4885 |
| US-20150087682-A1 | Method for Treating Scleroderma | TLR3, TLR4, TLR5 | TLR4 2/4885CYP1A2 4760/4885CYP2D6 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.